The Global Live Attenuated Vaccines Market is growing at a very reasonable pace. The Global Market for Live Attenuated Vaccines is growing continuously and expected to grow at a CAGR of 10.7% during the forecast period 2017-2027. According to a recent study report published by the Market Research Future the market is forecasted to demonstrate a spectacular growth by 2027, surpassing its previous growth records in terms of value with a prominent CAGR during the anticipated period (2017 – 2027).
Global Live Attenuated Vaccines Market – Key Players
Some of the key players in this market are: Pfizer Inc. (US), Sanofi Pasteur (US), Merck & Co., Inc. (US), Virbac (France), Bayer Healthcare (US), Barr Labs Inc.(US), Emergent BioSolutions (US), GlaxoSmithKline (US) , Protein Sciences Corp .(US), PaxVax (US), Medimmune (US) and others
Global Live Attenuated Vaccines Market – Segments
Global Live Attenuated Vaccines market has been segmented on the basis of types which consist of Measles, Polio, Smallpox, Rotavirus, Tuberculosis, Yellow fever, Varicella zoster and others. On the basis of end users which includes hospitals clinics and healthcare research institutes.
Get Sample report @ https://www.marketresearchfuture.com/sample_request/1101
Global Live Attenuated Vaccines Market – Insights
Vaccines created by reducing the virulence of pathogens are known as Live Attenuated Vaccines (LAV). These pathogens are weakened under laboratory conditions. The vaccine triggers a potent immune response against infectious diseases. They initiate memory cell production in order to respond to the pathogen that previously invaded the body. Increasing awareness about vaccination, growing government funding for vaccination programs and increasing prevalence of infectious diseases drive the growth of this market. Improving healthcare infrastructure, increasing demand for live attenuated vaccines, and emphasis on prevention of diseases also drives this market.
Availability of funds from government agencies, vaccination programs carried out across the region and technological advancement in vaccine production drive this market in America. World Health Organization (WHO) launched Global Vaccine Action Plan in May 2012 with a motive of strengthening immunization programs and reduce the occurrence of infectious diseases. It was a product of Decade of Vaccines Collaboration (DoV) and consisted of 194 member states. Guidelines were published by UNICEF and WHO to develop a plan for immunization. In 1963 the government introduced measles vaccine, which resulted into a significant decline in mortality rate caused by measles. States in the U.S have made vaccination mandatory before admitting a child to school. Schools are also taking a major initiative in vaccination of children.
Global Live Attenuated Vaccines Market – Competitive Analysis
The market for live attenuated vaccines is characterized by the presence of several well-established and small players, the global market of live attenuated vaccines appears to be highly competitive and fragmented. Global players are increasingly expanding their footprint in the emerging nations, making it putting pressure on the regional players, especially in terms of features such as type, product portfolios, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. These players possess state of art manufacturing facilities and strong sales and distribution network which have helped them to gain leadership position in the market.
For instance, companies like in September 2017, Merck has launched INNOVAX-ND-IBD, the first live vaccine made with biotechnology that protects against three highly infectious diseases in poultry Infectious Bursal Disease (IBD), Newcastle Disease (ND), and Marek’s disease (MD). When given to chickens either in ovo or subcutaneously in the hatchery, it provides life-long protection for ND, IBD and MD simultaneously.
Moreover, October 2017, Company named MedImmune a biotechnology company developing optimized therapeutic antibodies targeting AMHR2 for the treatment of cancer has entered into a licensing agreement under which GamaMabs will use MedImmune’s proprietary pyrrolobenzodiazepine (PBD) toxin and linker technology to research and produce an antibody-drug conjugate (ADC) as a potential cancer therapy.
Moreover, in July 2017, company named Emergent BioSolutions Inc. is licensing agreement with Valneva SE for global exclusive rights to Valneva’s Zika vaccine technology, ZIKV. This will help the company to acquire revenue-generating products and advancing products to aligning with partners such as Valneva to develop innovative products that could potentially serve the needs of both government customers and the commercial market.
Browse Complete 110 Pages Premium Research Report Enabled with 30+ Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/live-attenuated-vaccines-market-1101
Major Table of Content
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope of the Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312